Brogidirsen clinical trials
Also written NS-089/NCNP-02.
How each study uses brogidirsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the brogidirsen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
NS Pharma, Inc. (2) · Nippon Shinyaku Co., Ltd. (1) · National Center of Neurology and Psychiatry, Japan (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test brogidirsen.
- Feb 2027NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)Phase 2 · NS Pharma, Inc.
- Apr 2027Extension Study of NS-089/NCNP-02 in DMDPhase 2 · Nippon Shinyaku Co., Ltd.
Studies
Open first, then newest update. How each study uses brogidirsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular DystrophyEnrolling by invitationPhase 2NS Pharma, Inc.NCT07943598Written as Brogidirsen
- NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)Active, not recruitingPhase 2NS Pharma, Inc.NCT05996003Written as NS-089/NCNP-02
- Extension Study of NS-089/NCNP-02 in DMDActive, not recruitingPhase 2Nippon Shinyaku Co., Ltd.NCT05135663Written as NS-089/NCNP-02
- Exploratory Study of NS-089/NCNP-02 in DMDCompletedPhase 1/2National Center of Neurology and Psychiatry, JapanNCT04129294Written as NS-089/NCNP-02
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular DystrophyNov 17, 2026NCT07943598
Codes
What other systems call brogidirsen · ClinicalTrials.gg INT014888
- UNII (FDA) 4KM8P975UMBROGIDIRSENOne source FDA
- NCI Thesaurus C190319BrogidirsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4KM8P975UM | BROGIDIRSEN | One source FDA |
| NCI Thesaurus | C190319 | Brogidirsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.